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Clinical PerspectiveWhat Is New?Although the initial aortic valve replacement strategy improves prognosis of hemodialysis patients with severe aortic stenosis, the magnitude of its benefit is smaller in hemodialysis patients than in nonhemodialysis patients, which could at least in part be explained by the extremely high rate of aortic valve procedure--related death in hemodialysis patients.What Are the Clinical Implications?The initial aortic valve replacement is an effective procedure to treat hemodialysis patients with severe aortic stenosis, but there is an urgent unmet need to improve the procedural outcomes of aortic valve replacement in hemodialysis patients.

Introduction {#jah32311-sec-0008}
============

The number of patients with end‐stage renal disease requiring hemodialysis has been gradually increasing. In 2012, more than 400 000 American patients with end‐stage renal disease were on hemodialysis, including over 98 000 new patients.[1](#jah32311-bib-0001){ref-type="ref"} In Japan, more than 300 000 patients with end‐stage renal disease are on hemodialysis, and the candidate pool increases by over 30 000 patients per year.[2](#jah32311-bib-0002){ref-type="ref"} Dialysis patients are associated with a higher risk for the development of cardiovascular diseases with calcified degeneration of cardiac valves and/or heavy calcification of coronary arteries.[3](#jah32311-bib-0003){ref-type="ref"}, [4](#jah32311-bib-0004){ref-type="ref"}, [5](#jah32311-bib-0005){ref-type="ref"}, [6](#jah32311-bib-0006){ref-type="ref"} Calcified aortic stenosis (AS) is particularly common in hemodialysis patients, and has been found to be an independent risk factor for death in hemodialysis patients.[6](#jah32311-bib-0006){ref-type="ref"}, [7](#jah32311-bib-0007){ref-type="ref"} Regarding the clinical outcomes of hemodialysis patients with severe AS, there are only a few small studies suggesting the higher mortality and morbidity rates following surgical aortic valve replacement (AVR).[8](#jah32311-bib-0008){ref-type="ref"}, [9](#jah32311-bib-0009){ref-type="ref"}, [10](#jah32311-bib-0010){ref-type="ref"} However, the characteristics and prognosis of hemodialysis patients with severe AS have not yet been well defined in comparison with those in nonhemodialysis patients with severe AS. Also, it is not clear whether the effect size of the initial AVR strategy relative to the conservative strategy differs between hemodialysis patients and nonhemodialysis patients, although we previously reported that the initial AVR strategy was associated with markedly lower mortality risk than the conservative strategy in the asymptomatic patients with severe AS.[11](#jah32311-bib-0011){ref-type="ref"} Therefore, we sought to investigate the long‐term outcomes of hemodialysis patients with severe AS and to evaluate the effect of the initial AVR strategy relative to the conservative strategy in clinical outcomes compared between hemodialysis and nonhemodialysis patients in a large Japanese observational database of consecutive patients with severe AS.

Methods {#jah32311-sec-0009}
=======

Study Design and Patient Population {#jah32311-sec-0010}
-----------------------------------

The study design of the CURRENT AS (contemporary outcomes after surgery and medical treatment in patients with severe aortic stenosis) registry was previously described in detail.[11](#jah32311-bib-0011){ref-type="ref"} In brief, the CURRENT AS registry is a retrospective, multicenter registry that enrolled 3815 consecutive patients with severe AS from 27 centers (Appendix [S1](#jah32311-sup-0001){ref-type="supplementary-material"}, on‐site surgical facility in 20 centers) in Japan between January 2003 and December 2011. We examined the hospital database of transthoracic echocardiography and enrolled consecutive patients meeting the definition of severe AS (peak aortic jet velocity \>4.0 m/s, mean aortic pressure gradient \>40 mm Hg, or aortic valve area \<1.0 cm^2^) for the first time during the study period. We excluded patients with a history of aortic valve repair/replacement/plasty or percutaneous aortic balloon valvuloplasty. The institutional review boards in all 27 participating centers approved the protocol. Written informed consent from each patient was waived because clinical information was obtained from the routine practice, and no patient refused to participate in the study when contacted for follow‐up.

Among the 3815 study patients, there were 405 hemodialysis patients (initial AVR group: N=135 \[33.3%\], and conservative group: N=270) and 3410 nonhemodialysis patients (initial AVR group: N=1062 \[31.1%\], and conservative group: N=2348) at the time of the index echocardiography (Figure [1](#jah32311-fig-0001){ref-type="fig"}). The conservative group consisted of all the patients other than those in whom AVR was planned based on the index echocardiographic findings. The conservative management included watchful waiting for symptoms in asymptomatic patients, and medical management of angina and/or heart failure in symptomatic patients. There were 3 main reasons why AVR was not performed in the conservative group. First, patients were considered to have no formal AVR indications by their attending physician (1388 patients, 53.0%) either because of absence of symptoms (1067 patients) or improvement of symptoms by medication (237 patients). Second, patients had unacceptably high surgical risk (798 patients, 30.5%). Third, patients refused to undergo AVR (403 patients, 15.4%).

![Study flow chart. AS indicates aortic stenosis; AVR, aortic valve replacement.](JAH3-6-e004961-g001){#jah32311-fig-0001}

The effect of the initial AVR strategy relative to the conservative strategy was assessed based on the initial strategies regardless of the actual performance of AVR. The follow‐up was commenced on the day of the index echocardiography except for the analysis comparing the clinical outcomes after AVR between hemodialysis and nonhemodialysis patients, in which the follow‐up was commenced on the day of AVR.

Echocardiography {#jah32311-sec-0011}
----------------

All patients underwent a comprehensive 2‐dimensional and Doppler echocardiographic evaluation in each participating center. Peak aortic jet velocity and mean pressure gradient were obtained with the use of the simplified Bernoulli equation. Aortic valve area was calculated with the use of the standard continuity equation and was indexed by body surface area.[12](#jah32311-bib-0012){ref-type="ref"}

Data Collections and Definitions {#jah32311-sec-0012}
--------------------------------

Baseline clinical information was collected by reviewing the hospital charts or database. Follow‐up information was collected mainly by reviewing the hospital charts, and additional information was collected through contact with patients, their families, and/or referring physicians by sending mails regarding survival status, symptoms, and subsequent hospitalizations.

The primary outcome measure in the present analysis was all‐cause death. The secondary outcome measures included cardiovascular death, aortic valve--related death, aortic valve procedure--related death, sudden death, noncardiovascular death, hospitalization for heart failure (HF), and a composite of aortic valve--related death or hospitalization for HF. The causes of death were classified according to the Valve Academic Research Consortium definitions and were adjudicated by a clinical event committee (Data [S1](#jah32311-sup-0001){ref-type="supplementary-material"}).[13](#jah32311-bib-0013){ref-type="ref"}, [14](#jah32311-bib-0014){ref-type="ref"} Aortic valve--related death included aortic valve procedure--related death, sudden death, and death attributable to HF possibly related to the aortic valve. Hospitalization for HF was defined as hospitalization because of worsening HF requiring intravenous drug therapy.

Statistical Analysis {#jah32311-sec-0013}
--------------------

Categorical variables are presented as numbers and percentages and were compared with the χ^2^ test or Fisher exact test. Continuous variables are presented as the mean and SD or median and interquartile range. Continuous variables were compared using Student *t* test or Wilcoxon rank sum test based on their distributions. The Kaplan--Meier method was used to calculate the cumulative incidence of events, and the differences were assessed with the log‐rank test.

The Cox proportional hazard models were used to estimate the adjusted risk of hemodialysis patients relative to nonhemodialysis patients or the adjusted risk of initial AVR strategy relative to conservative strategy for all‐cause death, cardiovascular death, aortic valve--related death, aortic valve procedure--related death, sudden death, noncardiovascular death, hospitalization for HF, and a composite of aortic valve--related death and hospitalization for HF. We selected 20 clinically relevant factors listed in Table [1](#jah32311-tbl-0001){ref-type="table-wrap"} and Tables [S1](#jah32311-sup-0001){ref-type="supplementary-material"} and [S2](#jah32311-sup-0001){ref-type="supplementary-material"} as the risk‐adjusting variables consistent with the previous report. We constructed parsimonious models with a limited number of variables for aortic valve procedure--related death, because the number of patients with this event was too small for the nonparsimonious model. We selected 6 clinically relevant variables as the risk‐adjusted variables as listed in Table [1](#jah32311-tbl-0001){ref-type="table-wrap"} and Tables [S1](#jah32311-sup-0001){ref-type="supplementary-material"} and [S2](#jah32311-sup-0001){ref-type="supplementary-material"} in the parsimonious models. The centers were incorporated into all the models as the stratification variable. With the exception of age, the continuous variables were dichotomized by the median values or clinically meaningful reference values. Because the differences in the age distributions between the hemodialysis and nonhemodialysis groups and between the initial AVR and conservative strategies were too large to allow the dichotomous approach, we treated age as a continuous variable in the Cox proportional hazard models. The risks for the clinical end points were expressed as hazard ratios and their 95% CI. We also evaluated the interaction between hemodialysis/nonhemodialysis subgroups and the effect of the initial AVR strategy relative to the conservative strategy for the primary and secondary outcome measures.

###### 

Baseline Characteristics: Dialysis VS Nondialysis Patients

  Variables                                                                                                                               Dialysis Patients (N=405)   Nondialysis Patients (N=3410)   *P* Value
  --------------------------------------------------------------------------------------------------------------------------------------- --------------------------- ------------------------------- -----------
  Age, y                                                                                                                                  73.2±8.6                    78.3±9.7                        \<0.001
  Age ≥80 y[a](#jah32311-note-0004){ref-type="fn"}, [b](#jah32311-note-0005){ref-type="fn"}                                               93 (23)                     1636 (48)                       \<0.001
  Men[a](#jah32311-note-0004){ref-type="fn"}                                                                                              242 (60)                    1201 (35)                       \<0.001
  Body mass index[c](#jah32311-note-0006){ref-type="fn"}                                                                                  20.5±3.6                    21.9±3.8                        \<0.001
  Body mass index \<22[a](#jah32311-note-0004){ref-type="fn"}                                                                             298 (74)                    2028 (59)                       \<0.001
  Body surface area, m^2^                                                                                                                 1.46±0.18                   1.46±0.19                       0.47
  Initial treatment strategies                                                                                                                                                                        0.37
  Initial AVR strategy[a](#jah32311-note-0004){ref-type="fn"}                                                                             135 (33)                    1062 (31)                       
  Conservative strategy[a](#jah32311-note-0004){ref-type="fn"}                                                                            270 (67)                    2348 (69)                       
  Any symptoms possibly related to aortic stenosis                                                                                        198 (49)                    1807 (53)                       0.12
  Angina                                                                                                                                  60 (15)                     438 (13)                        0.27
  Syncope                                                                                                                                 25 (6)                      173 (5)                         0.34
  Heart failure                                                                                                                           143 (35)                    1460 (43)                       0.004
  Admission for heart failure at index echocardiography[a](#jah32311-note-0004){ref-type="fn"}, [b](#jah32311-note-0005){ref-type="fn"}   60 (15)                     730 (21)                        0.002
  Hypertension[a](#jah32311-note-0004){ref-type="fn"}                                                                                     287 (71)                    2380 (70)                       0.66
  Current smoking[a](#jah32311-note-0004){ref-type="fn"}                                                                                  22 (5)                      174 (5)                         0.78
  History of smoking                                                                                                                      120 (30)                    710 (21)                        \<0.001
  Dyslipidemia                                                                                                                            78 (19)                     1249 (37)                       \<0.001
  On statin therapy                                                                                                                       45 (11)                     925 (27)                        \<0.001
  Diabetes mellitus                                                                                                                       127 (31)                    770 (23)                        \<0.001
  On insulin therapy[a](#jah32311-note-0004){ref-type="fn"}                                                                               36 (9)                      152 (4)                         \<0.001
  Prior myocardial infarction[a](#jah32311-note-0004){ref-type="fn"}                                                                      48 (12)                     275 (8)                         0.01
  Prior percutaneous coronary intervention                                                                                                97 (24)                     405 (12)                        \<0.001
  Prior coronary artery bypass grafting                                                                                                   45 (11)                     154 (5)                         \<0.001
  Prior open heart surgery                                                                                                                51 (13)                     265 (8)                         \<0.001
  Prior symptomatic stroke[a](#jah32311-note-0004){ref-type="fn"}                                                                         70 (17)                     433 (13)                        0.01
  Atrial fibrillation or flutter[a](#jah32311-note-0004){ref-type="fn"}, [b](#jah32311-note-0005){ref-type="fn"}                          100 (25)                    728 (21)                        0.12
  Aortic/peripheral vascular disease[a](#jah32311-note-0004){ref-type="fn"}                                                               82 (20)                     200 (6)                         \<0.001
  Serum creatinine, mg/dL                                                                                                                                             0.83 (0.68--1.1)                
  Years from dialysis introduction                                                                                                                                                                    
   \<1 y                                                                                                                                  33 (8)                                                      
   ≥1 y, \<5 y                                                                                                                            116 (29)                                                    
   ≥5 y, \<10 y                                                                                                                           87 (21)                                                     
   ≥10 y                                                                                                                                  169 (42)                                                    
  Anemia[a](#jah32311-note-0004){ref-type="fn"}, [d](#jah32311-note-0007){ref-type="fn"}                                                  335 (83)                    1782 (52)                       \<0.001
  Liver cirrhosis (Child‐Pugh B or C)[a](#jah32311-note-0004){ref-type="fn"}                                                              6 (1)                       32 (1)                          0.29
  Malignancy                                                                                                                              59 (15)                     458 (13)                        0.53
  Malignancy currently under treatment[a](#jah32311-note-0004){ref-type="fn"}, [b](#jah32311-note-0005){ref-type="fn"}                    13 (3)                      136 (4)                         0.44
  Chest wall irradiation                                                                                                                  2 (0.5)                     23 (1)                          1.0
  Immunosuppressive therapy                                                                                                               17 (4)                      114 (3)                         0.37
  Chronic lung disease                                                                                                                    40 (10)                     360 (11)                        0.67
  Chronic lung disease (moderate or severe)[a](#jah32311-note-0004){ref-type="fn"}                                                        11 (3)                      101 (3)                         0.78
  Coronary artery disease[a](#jah32311-note-0004){ref-type="fn"}                                                                          195 (48)                    949 (28)                        \<0.001
  Logistic EuroSCORE, %                                                                                                                   13.4 (7.9--23.0)            9.4 (5.5--16.1)                 \<0.001
  EuroSCORE II, %                                                                                                                         2.7 (1.9--4.6)              2.9 (1.6--4.9)                  0.10
  STS‐PROM score, %                                                                                                                       8.5 (5.6--12.3)             3.5 (2.1--5.7)                  \<0.001
  Etiology of aortic stenosis                                                                                                                                                                         \<0.001
  Degenerative                                                                                                                            394 (97)                    2985 (88)                       
  Congenital (unicuspid, bicuspid, quadricuspid)                                                                                          4 (1)                       254 (7)                         
  Rheumatic                                                                                                                               5 (1)                       145 (4)                         
  Infective endocarditis                                                                                                                  1 (0.3)                     6 (0.2)                         
  Others                                                                                                                                  1 (0.3)                     20 (0.6)                        
  Echocardiographic variables                                                                                                                                                                         
  Left ventricular end‐diastolic diameter, mm                                                                                             48.9±7.2                    45.6±6.9                        \<0.001
  Left ventricular end‐systolic diameter, mm                                                                                              34.2±8.8                    29.8±7.7                        \<0.001
  Left ventricular ejection fraction, %                                                                                                   56.9±14.0                   63.5±13.3                       \<0.001
  Left ventricular ejection fraction \<40%                                                                                                57 (14)                     236 (7)                         \<0.001
  Left ventricular ejection fraction \<50%                                                                                                105 (26)                    488 (14)                        \<0.001
  Interventricular septum thickness in diastole, mm                                                                                       11.7±2.3                    11.3±2.3                        \<0.001
  Posterior wall thickness in diastole, mm                                                                                                11.4±2.0                    10.9±2.0                        \<0.001
  Peak aortic jet velocity, m/s                                                                                                           3.96±0.87                   4.16±0.92                       \<0.001
  Peak aortic jet velocity ≥5 m/s                                                                                                         52 (13)                     646 (19)                        0.003
  Peak aortic jet velocity ≥4 m/s[a](#jah32311-note-0004){ref-type="fn"}, [b](#jah32311-note-0005){ref-type="fn"}                         211 (52)                    1974 (58)                       0.03
  Peak aortic pressure gradient, mm Hg                                                                                                    66±28                       72±32                           \<0.001
  Mean aortic pressure gradient, mm Hg                                                                                                    37±17                       41±20                           \<0.001
  Aortic valve area (equation of continuity), cm^2^                                                                                       0.74±0.17                   0.72±0.19                       0.03
  Aortic valve area index, cm^2^/m^2^                                                                                                     0.51±0.12                   0.50±0.13                       0.18
  Any combined valvular disease (moderate or severe)[a](#jah32311-note-0004){ref-type="fn"}, [b](#jah32311-note-0005){ref-type="fn"}      166 (41)                    1392 (41)                       0.95
  Moderate or severe aortic regurgitation                                                                                                 77 (19)                     714 (21)                        0.37
  Moderate or severe mitral stenosis                                                                                                      14 (3)                      119 (3)                         0.97
  Moderate or severe mitral regurgitation                                                                                                 102 (25)                    661 (19)                        0.006
  Moderate or severe tricuspid regurgitation                                                                                              64 (16)                     564 (17)                        0.71
  Tricuspid regurgitation pressure gradient ≥40 mm Hg[a](#jah32311-note-0004){ref-type="fn"}                                              80 (20)                     526 (15)                        0.02

Values are number (%), mean±SD, or median (interquartile range) unless otherwise stated. AVR indicates aortic valve replacement; PROM, predicted risk of mortality; STS, Society of Thoracic Surgeons.

Potential independent variables selected in the Cox proportional hazard models for all‐cause death, cardiovascular death, aortic valve--related death, sudden death, noncardiovascular death, hospitalization for heart failure, and a composite of aortic valve--related death or hospitalization for heart failure.

Potential independent variables selected in the Cox proportional hazard models for aortic valve procedure--related death.

Body mass index was calculated as weight in kilograms divided by height in meters squared.

Anemia was defined by the World Health Organization criteria (hemoglobin \<12.0 g/dL in women and \<13.0 g/dL in men).

All statistical analyses were conducted by 2 physicians (Y.K. and T.T.) and a statistician (T.M.) with the use of JMP 10.0.2 or SAS 9.4. All reported *P* values were 2‐tailed, and *P*\<0.05 was considered statistically significant.

Results {#jah32311-sec-0014}
=======

Baseline Characteristics and Clinical Outcomes: Hemodialysis Versus Nonhemodialysis Patients {#jah32311-sec-0015}
--------------------------------------------------------------------------------------------

Baseline characteristics were significantly different between hemodialysis patients and nonhemodialysis patients (Table [1](#jah32311-tbl-0001){ref-type="table-wrap"}).

The median follow‐up period after the index echocardiography was 1361 (interquartile range: 1055--1697) days, with a 90% follow‐up rate at 2 years. Cumulative 5‐year incidence of the first surgical AVR or transcatheter aortic valve implantation (TAVI) was significantly higher in hemodialysis patients than in nonhemodialysis patients in the entire study population as well as in the conservatively managed population (Figure [2](#jah32311-fig-0002){ref-type="fig"} and Figure [S1](#jah32311-sup-0001){ref-type="supplementary-material"}). TAVI was performed in 40 patients including 1 hemodialysis patient during the follow‐up period.

![Cumulative incidence of surgical AVR or TAVI: dialysis vs nondialysis patients. Follow‐up was commenced on the day of the index echocardiography. AVR indicates aortic valve replacement; TAVI, transcatheter aortic valve implantation.](JAH3-6-e004961-g002){#jah32311-fig-0002}

Cumulative 5‐year incidence of the primary outcome measure (all‐cause death) was significantly higher in hemodialysis patients than in nonhemodialysis patients (71% versus 40%, *P*\<0.001) with a notably higher rate in the first year (35.9% versus 13.4%) after the index echocardiography (Table [2](#jah32311-tbl-0002){ref-type="table-wrap"} and Figure [3](#jah32311-fig-0003){ref-type="fig"}). The risk for sudden death was markedly higher in hemodialysis patients than in nonhemodialysis patients (Table [2](#jah32311-tbl-0002){ref-type="table-wrap"} and Figure [3](#jah32311-fig-0003){ref-type="fig"}). Cumulative 5‐year incidence of hospitalization for HF was not significantly different between hemodialysis and nonhemodialysis patients (Table [3](#jah32311-tbl-0003){ref-type="table-wrap"}). The results from the adjusted analysis were fully consistent with those from the unadjusted analysis (Table [3](#jah32311-tbl-0003){ref-type="table-wrap"}).

###### 

Clinical Outcomes: Dialysis VS Nondialysis Patients

                                                                                    Dialysis Patients   Nondialysis Patients   Unadjusted HR (95% CI)   *P* Value   Adjusted HR (95% CI)   *P* Value
  --------------------------------------------------------------------------------- ------------------- ---------------------- ------------------------ ----------- ---------------------- -----------
  All‐cause death                                                                   248 (71.0)          1201 (40.0)            2.69 (2.34--3.08)        \<0.001     2.76 (2.35--3.25)      \<0.001
  Cardiovascular death                                                              183 (59.5)          769 (27.8)             3.07 (2.60--3.60)        \<0.001     3.18 (2.62--3.86)      \<0.001
  Aortic valve--related death                                                       107 (36.1)          502 (19.2)             2.69 (2.17--3.31)        \<0.001     3.10 (2.41--3.98)      \<0.001
  Aortic valve procedure--related death                                             32 (9.9)            49 (1.9)               7.02 (4.44--10.93)       \<0.001     6.74 (4.17--10.91)     \<0.001
  Sudden death                                                                      52 (24.7)           144 (5.7)              4.70 (3.38--6.43)        \<0.001     4.80 (3.23--7.14)      \<0.001
  Noncardiovascular death                                                           65 (28.5)           432 (16.9)             2.00 (1.52--2.57)        \<0.001     2.05 (1.52--2.77)      \<0.001
  Hospitalization for heart failure                                                 57 (31.9)           755 (29.2)             0.96 (0.72--1.24)        0.76        0.84 (0.63--1.13)      0.26
  A composite of aortic valve--related death or hospitalization for heart failure   136 (51.6)          936 (34.1)             1.78 (1.48--2.12)        \<0.001     1.63 (1.33--2.00)      \<0.001

Number of patients with at least 1 event was counted through the entire follow‐up period, while the cumulative incidence was truncated at 5 years. Follow‐up was commenced on the day of the index echocardiography. HR indicates hazard ratio.

![Cumulative incidence of all‐cause death and sudden death: dialysis vs nondialysis patients. Follow‐up was commenced on the day of the index echocardiography.](JAH3-6-e004961-g003){#jah32311-fig-0003}

###### 

Baseline Characteristics in Dialysis and Nondialysis Patients: Initial AVR VS Conservative Groups

  Variables                                                                                                                               Dialysis Patients   Nondialysis Patients                                               
  --------------------------------------------------------------------------------------------------------------------------------------- ------------------- ---------------------- --------- ---------------- ---------------- ---------
  Age, y                                                                                                                                  70.3±8.2            74.7±8.4               \<0.001   73.7±8.9         80.3±9.4         \<0.001
  Age ≥80 y[a](#jah32311-note-0010){ref-type="fn"}, [b](#jah32311-note-0011){ref-type="fn"}                                               17 (13)             76 (28)                \<0.001   282 (27)         1354 (58)        \<0.001
  Men[a](#jah32311-note-0010){ref-type="fn"}                                                                                              87 (64)             155 (57)               0.17      420 (40)         781 (33)         \<0.001
  Body mass index[c](#jah32311-note-0012){ref-type="fn"}                                                                                  20.8±3.1            20.3±3.9               0.24      22.5±3.6         21.7±3.9         \<0.001
  Body mass index \<22[a](#jah32311-note-0010){ref-type="fn"}                                                                             95 (70)             203 (75)               0.30      527 (50)         1501 (64)        \<0.001
  Any symptoms possibly related to aortic stenosis                                                                                        103 (76)            95 (35)                \<0.001   802 (76)         1005 (43)        \<0.001
  Angina                                                                                                                                  33 (24)             27 (10)                \<0.001   258 (24)         180 (8)          \<0.001
  Syncope                                                                                                                                 15 (11)             10 (4)                 0.007     95 (9)           78 (3)           \<0.001
  Heart failure                                                                                                                           72 (53)             71 (26)                \<0.001   587 (55)         873 (37)         \<0.001
  Admission for heart failure at index echocardiography[a](#jah32311-note-0010){ref-type="fn"}, [b](#jah32311-note-0011){ref-type="fn"}   28 (21)             32 (12)                0.02      242 (23)         488 (21)         0.19
  Hypertension[a](#jah32311-note-0010){ref-type="fn"}                                                                                     97 (72)             190 (70)               0.76      710 (67)         1670 (71)        0.01
  Current smoking[a](#jah32311-note-0010){ref-type="fn"}                                                                                  12 (9)              10 (4)                 0.03      71 (7)           103 (4)          0.005
  Diabetes mellitus on insulin therapy[a](#jah32311-note-0010){ref-type="fn"}                                                             11 (8)              25 (9)                 0.71      47 (4)           105 (4)          0.95
  Prior myocardial infarction[a](#jah32311-note-0010){ref-type="fn"}                                                                      11 (8)              37 (14)                0.10      40 (4)           235 (10)         \<0.001
  Prior open heart surgery                                                                                                                12 (9)              39 (14)                0.11      36 (3)           229 (10)         \<0.001
  Prior symptomatic stroke[a](#jah32311-note-0010){ref-type="fn"}                                                                         19 (14)             51 (19)                0.23      88 (8)           345 (15)         \<0.001
  Atrial fibrillation or flutter[a](#jah32311-note-0010){ref-type="fn"}, [b](#jah32311-note-0011){ref-type="fn"}                          29 (21)             71 (26)                0.29      178 (17)         550 (23)         \<0.001
  Aortic/peripheral vascular disease[a](#jah32311-note-0010){ref-type="fn"}                                                               12 (9)              70 (26)                \<0.001   58 (5)           142 (6)          0.50
  Years from dialysis introduction                                                                                                                                                   0.21                                        
  \<1 y                                                                                                                                   8 (6)               25 (9)                                                             
  ≥1 y, \<5 y                                                                                                                             33 (24)             83 (31)                                                            
  ≥5 y, \<10 y                                                                                                                            29 (21)             58 (21)                                                            
  ≥10 y                                                                                                                                   65 (48)             104 (39)                                                           
  Anemia[a](#jah32311-note-0010){ref-type="fn"}, [d](#jah32311-note-0013){ref-type="fn"}                                                  121 (90)            214 (79)               0.009     508 (48)         1274 (54)        \<0.001
  Liver cirrhosis (Child‐Pugh B or C)[a](#jah32311-note-0010){ref-type="fn"}                                                              2 (1)               4 (1)                  1.0       4 (0.4)          28 (1)           0.02
  Malignancy currently under treatment[a](#jah32311-note-0010){ref-type="fn"}, [b](#jah32311-note-0011){ref-type="fn"}                    2 (1)               11 (4)                 0.23      22 (2)           114 (5)          \<0.001
  Chronic lung disease (moderate or severe)[a](#jah32311-note-0010){ref-type="fn"}                                                        5 (4)               6 (2)                  0.52      14 (1)           87 (4)           \<0.001
  Coronary artery disease[a](#jah32311-note-0010){ref-type="fn"}                                                                          76 (56)             119 (44)               0.02      322 (30)         627 (27)         0.03
  STS‐PROM score, %                                                                                                                       7.3 (4.8--11.4)     8.9 (5.9--13.0)        0.007     2.5 (1.6--4.1)   3.9 (2.4--6.7)   \<0.001
  Echocardiographic variables                                                                                                                                                                                                    
  Left ventricular ejection fraction, %[a](#jah32311-note-0010){ref-type="fn"}                                                            58.1±13.2           56.4±14.4              0.25      63.4±14.0        63.5±12.9        0.72
  Left ventricular ejection fraction \<50%                                                                                                32 (24)             73 (27)                0.47      173 (16)         315 (13)         0.03
  Peak aortic jet velocity, m/s                                                                                                           4.41±0.82           3.74±0.80              \<0.001   4.74±0.82        3.89±0.84        \<0.001
  Peak aortic jet velocity ≥4 m/s[a](#jah32311-note-0010){ref-type="fn"}, [b](#jah32311-note-0011){ref-type="fn"}                         100 (74)            111 (41)               \<0.001   894 (84)         1080 (46)        \<0.001
  Mean aortic pressure gradient, mm Hg                                                                                                    49±18               32±15                  \<0.001   54±20            36±17            \<0.001
  Aortic valve area (equation of continuity), cm^2^                                                                                       0.69±0.16           0.76±0.16              \<0.001   0.64±0.17        0.75±0.18        \<0.001
  Any combined valvular disease (moderate or severe)[a](#jah32311-note-0010){ref-type="fn"}, [b](#jah32311-note-0011){ref-type="fn"}      65 (48)             101 (37)               0.04      414 (39)         978 (42)         0.14
  Tricuspid regurgitation pressure gradient ≥40 mm Hg[a](#jah32311-note-0010){ref-type="fn"}                                              32 (24)             48 (18)                0.16      148 (14)         378 (16)         0.11

Values are number (%), mean±SD, or median (interquartile range) unless otherwise stated. AVR indicates aortic valve replacement; PROM, predicted risk of mortality; STS, Society of Thoracic Surgeons.

Potential independent variables selected in the Cox proportional hazard models for all‐cause death, cardiovascular death, and a composite of aortic valve--related death or hospitalization for heart failure.

Potential independent variables selected in the Cox proportional hazard models for aortic valve--related death, aortic valve--procedure death, sudden death, noncardiovascular death, and hospitalization for heart failure.

Body mass index was calculated as weight in kilograms divided by height in meters squared.

Anemia was defined by the World Health Organization criteria (hemoglobin \<12.0 g/dL in women and \<13.0 g/dL in men).

Baseline Characteristics and Clinical Outcomes in Hemodialysis and Nonhemodialysis Patients: Initial AVR Versus Conservative Strategies {#jah32311-sec-0016}
---------------------------------------------------------------------------------------------------------------------------------------

The differences in baseline characteristics between the initial AVR and conservative groups were basically consistent in both hemodialysis and nonhemodialysis patients. Surgical risk scores were significantly lower in the initial AVR group than in the conservative group. Patients in the initial AVR group had greater echocardiographic AS severity and left ventricular wall thickness than those in the conservative group (Table [3](#jah32311-tbl-0003){ref-type="table-wrap"}, Table [S1](#jah32311-sup-0001){ref-type="supplementary-material"}).

In both hemodialysis and nonhemodialysis patients, cumulative 5‐year incidence of all‐cause death was significantly lower in the initial AVR group than in the conservative group (Table [4](#jah32311-tbl-0004){ref-type="table-wrap"} and Figure [4](#jah32311-fig-0004){ref-type="fig"}). However, the effect size of the initial AVR strategy relative to the conservative strategy on mortality was smaller in hemodialysis patients than in nonhemodialysis patients (adjusted hazard ratio 0.62, 95% CI 0.43--0.90, *P*=0.01, and adjusted hazard ratio 0.40, 95% CI 0.33--0.48, *P*\<0.001, *P* interaction=0.001) (Table [4](#jah32311-tbl-0004){ref-type="table-wrap"}). In both hemodialysis and nonhemodialysis patients, the lower risks of the initial AVR group relative to the conservative group were highly significant for sudden death and HF hospitalization (Table [4](#jah32311-tbl-0004){ref-type="table-wrap"} and Figure [4](#jah32311-fig-0004){ref-type="fig"}). In addition, we have conducted a propensity‐score matched analysis as a sensitivity analysis and analyzed the initial AVR versus conservative groups in hemodialysis and nonhemodialysis patients, respectively. The results of sensitivity analysis were similar to those of the primary analysis (Tables [S3](#jah32311-sup-0001){ref-type="supplementary-material"} through [S6](#jah32311-sup-0001){ref-type="supplementary-material"} and Figures [S2](#jah32311-sup-0001){ref-type="supplementary-material"} and [S3](#jah32311-sup-0001){ref-type="supplementary-material"}).

###### 

Clinical Outcomes in Dialysis and Nondialysis Patients: Initial AVR VS Conservative Groups

                                                                                           Initial AVR Group   Conservative Group   Unadjusted HR (95% CI)   *P* Value   Adjusted HR (95% CI)   *P* Value   *P* Interaction
  ---------------------------------------------------------------------------------------- ------------------- -------------------- ------------------------ ----------- ---------------------- ----------- -----------------
  All‐cause death                                                                                                                                                                                           0.001
  Dialysis patients                                                                        66 (60.6)           182 (75.5)           0.61 (0.46--0.81)        \<0.001     0.62 (0.43--0.90)      0.01        
  Nondialysis patients                                                                     170 (18.7)          1031 (49.3)          0.30 (0.25--0.35)        \<0.001     0.40 (0.33--0.48)      \<0.001     
  Cardiovascular death                                                                                                                                                                                      0.004
  Dialysis patients                                                                        48 (48.6)           135 (64.5)           0.61 (0.43--0.84)        0.002       0.64 (0.41--0.98)      0.04        
  Nondialysis patients                                                                     103 (11.3)          666 (35.6)           0.28 (0.23--0.35)        \<0.001     0.36 (0.28--0.45)      \<0.001     
  Aortic valve--related death                                                                                                                                                                               \<0.001
  Dialysis patients                                                                        27 (21.8)           80 (44.6)            0.60 (0.38--0.91)        0.02        0.57 (0.34--0.94)      0.03        
  Nondialysis patients                                                                     41 (4.2)            461 (26.7)           0.16 (0.12--0.23)        \<0.001     0.18 (0.13--0.26)      \<0.001     
  Aortic valve procedure--related death                                                                                                                                                                     0.005
  Dialysis patients                                                                        26 (21.2)           6 (3.4)              8.19 (3.60--22.00)       \<0.001     7.99 (2.91--21.93)     \<0.001     
  Nondialysis patients                                                                     24 (2.3)            25 (1.8)             1.87 (1.07--3.28)        0.03        1.43 (0.75--2.73)      0.28        
  Sudden death                                                                                                                                                                                              0.06
  Dialysis patients                                                                        4 (10.2)            48 (31.7)            0.14 (0.04--0.35)        \<0.001     0.15 (0.05--0.44)      \<0.001     
  Nondialysis patients                                                                     23 (3.0)            121 (7.2)            0.35 (0.22--0.54)        \<0.001     0.38 (0.23--0.62)      \<0.001     
  Noncardiovascular death                                                                                                                                                                                   0.11
  Dialysis patients                                                                        18 (23.4)           47 (30.9)            0.64 (0.36--1.09)        0.10        0.73 (0.37--1.45)      0.37        
  Nondialysis patients                                                                     67 (8.3)            365 (21.3)           0.33 (0.26--0.43)        \<0.001     0.50 (0.37--0.67)      \<0.001     
  Hospitalization for heart failure                                                                                                                                                                         0.66
  Dialysis patients                                                                        10 (26.9)           47 (31.7)            0.32 (0.15--0.61)        \<0.001     0.16 (0.06--0.42)      \<0.001     
  Nondialysis patients                                                                     92 (10.5)           663 (38.7)           0.23 (0.19--0.29)        \<0.001     0.24 (0.19--0.31)      \<0.001     
  A composite of aortic valve--related death or hospitalization because of heart failure                                                                                                                    0.01
  Dialysis patients                                                                        36 (42.2)           100 (56.1)           0.59 (0.40--0.85)        0.005       0.62 (0.38--1.02)      0.06        
  Nondialysis patients                                                                     129 (13.9)          807 (44.0)           0.27 (0.23--0.33)        \<0.001     0.27 (0.22--0.33)      \<0.001     

Number of patients with at least 1 event was counted through the entire follow‐up period, while the cumulative incidence was truncated at 5 years. Follow‐up was commenced on the day of the index echocardiography. AVR indicates aortic valve replacement; HR, hazard ratio.

![Cumulative incidence of all‐cause death (A) and sudden death (B) in dialysis patients and nondialysis patients: initial AVR vs conservative strategies. Follow‐up was commenced on the day of the index echocardiography. AVR indicates aortic valve replacement.](JAH3-6-e004961-g004){#jah32311-fig-0004}

Baseline Characteristics and Clinical Outcomes After AVR: Hemodialysis Versus Nonhemodialysis Patients {#jah32311-sec-0017}
------------------------------------------------------------------------------------------------------

Among the 135 hemodialysis and 1062 nonhemodialysis patients in the initial AVR group, surgical AVR or TAVI was actually performed in 131 patients (97%) and 1043 patients (98%), respectively. TAVI was performed only in 11 nonhemodialysis patients. The differences in baseline clinical and echocardiographic characteristics between hemodialysis and nonhemodialysis patients in the initial AVR group were consistent with those in the entire study population (Table [S2](#jah32311-sup-0001){ref-type="supplementary-material"}). The procedural characteristics in 1174 patients who actually underwent AVR based on the initial treatment strategy are presented in Table [S3](#jah32311-sup-0001){ref-type="supplementary-material"}. Hemodialysis patients more often underwent AVR combined with coronary artery bypass grafting and less often AVR combined with replacement of ascending aorta than nonhemodialysis patients. A bioprosthetic valve was less often used in hemodialysis patients than in nonhemodialysis patients (Table [S7](#jah32311-sup-0001){ref-type="supplementary-material"}). Hemodialysis patients were associated with markedly higher risk for all‐cause death and aortic valve procedure--related death after AVR than nonhemodialysis patients (Table [5](#jah32311-tbl-0005){ref-type="table-wrap"}, Figure [5](#jah32311-fig-0005){ref-type="fig"}). The 30‐day mortality rate after AVR was 7.6% in hemodialysis patients, which was markedly higher than 1.3% in nonhemodialysis patients (Figure [5](#jah32311-fig-0005){ref-type="fig"}). The rate of aortic valve procedure--related death, which predominantly occurred within 6 months of the AVR procedure, was markedly higher in the hemodialysis patients than in the nonhemodialysis patients (21.2% and 2.3%, *P*\<0.001) (Table [5](#jah32311-tbl-0005){ref-type="table-wrap"} and Figure [5](#jah32311-fig-0005){ref-type="fig"}). In hemodialysis patients, the cumulative 5‐year incidences of all‐cause death and hospitalization for HF were not significantly different between the bioprosthetic and mechanical valves (Figure [S4](#jah32311-sup-0001){ref-type="supplementary-material"}). Only 2 patients underwent redo AVR in the 80 hemodialysis patients who received the bioprosthetic valve.

###### 

Clinical Outcomes After AVR: Dialysis VS Nondialysis Patients

                                                                                    Dialysis Patients   Nondialysis Patients   Unadjusted HR (95% CI)   *P* Value   Adjusted HR (95% CI)   *P* Value
  --------------------------------------------------------------------------------- ------------------- ---------------------- ------------------------ ----------- ---------------------- -----------
  All‐cause death                                                                   64 (63.2)           156 (17.9)             5.19 (3.84--6.93)        \<0.001     4.00 (2.75--5.81)      \<0.001
  Cardiovascular death                                                              47 (52.6)           92 (10.7)              6.24 (4.34--8.86)        \<0.001     5.30 (3.32--8.48)      \<0.001
  Aortic valve--related death                                                       26 (21.2)           30 (3.0)               8.22 (4.82--13.94)       \<0.001     9.31 (5.20--16.68)     \<0.001
  Aortic valve procedure--related death                                             26 (21.2)           24 (2.3)               10.12 (5.78--17.78)      \<0.001     10.86 (5.87--20.07)    \<0.001
  Noncardiovascular death                                                           17 (22.4)           64 (8.0)               3.57 (2.02--5.99)        \<0.001     4.87 (2.69--8.82)      \<0.001
  Hospitalization for heart failure                                                 9 (25.6)            84 (9.8)               1.43 (0.67--2.70)        0.33        1.65 (0.80--3.40)      0.18
  A composite of aortic valve--related death or hospitalization for heart failure   34 (40.8)           112 (12.3)             3.63 (2.43--5.28)        \<0.001     2.90 (1.80--4.66)      \<0.001

Number of patients with at least 1 event was counted through the entire follow‐up period, while the cumulative incidence was truncated at 5 years. Follow‐up was commenced on the day of surgical AVR or TAVI. AVR indicates aortic valve replacement; HR, hazard ratio; TAVI, transcatheter aortic valve implantation.

![Cumulative incidence of all‐cause death and aortic valve procedure--related death after surgical AVR/TAVI in the initial AVR group: dialysis vs nondialysis patients. In the initial AVR group, 1174 of 1197 patients actually underwent surgical AVR or TAVI. Follow‐up was commenced on the day of surgical AVR or TAVI. AVR indicates aortic valve replacement; TAVI, transcatheter aortic valve implantation.](JAH3-6-e004961-g005){#jah32311-fig-0005}

Discussion {#jah32311-sec-0018}
==========

The main findings of the present study are as follows: (1) Hemodialysis patients with severe AS have a significantly poorer prognosis than nonhemodialysis patients with severe AS; (2) The initial AVR strategy as compared with the conservative strategy in hemodialysis patients was associated with significantly lower long‐term mortality risk, particularly the risk for sudden death; (3) However, the AVR procedure‐related mortality was much higher in hemodialysis patients than that in nonhemodialysis patients.

Previous small studies have suggested the poor prognosis after AVR in hemodialysis patients with severe AS.[6](#jah32311-bib-0006){ref-type="ref"}, [7](#jah32311-bib-0007){ref-type="ref"}, [8](#jah32311-bib-0008){ref-type="ref"}, [9](#jah32311-bib-0009){ref-type="ref"}, [10](#jah32311-bib-0010){ref-type="ref"} The present study including a large number of hemodialysis patients with severe AS clearly demonstrated that hemodialysis patients had a significantly higher 5‐year cumulative mortality rate than nonhemodialysis patients (71% versus 40%) with a notably higher rate in the first year (35.9% versus 13.4%), although AVR was more often performed in hemodialysis patients than in nonhemodialysis patients. Compared with the survival rates of 89.7% at 1 year and 60.5% at 5 years after hemodialysis introduction reported from the Society for Dialysis Therapy, the mortality rate of our study is considerably higher, suggesting the grimmer prognosis of hemodialysis patients with severe AS, although the durations after the hemodialysis introduction were variable in the present study.[2](#jah32311-bib-0002){ref-type="ref"} Furthermore, the rate of sudden death in hemodialysis patients was remarkably high (9.3% at 1 year and 24.7% at 5 years) in the present study. The 5‐year rate of sudden death was much higher than 10.5% at 4 years after percutaneous coronary intervention reported in Japanese hemodialysis patients.[15](#jah32311-bib-0015){ref-type="ref"}

AVR is the only definitive treatment in patients with severe AS. In the present study, the initial AVR strategy as compared with the conservative strategy was associated with a significantly lower long‐term mortality rate in hemodialysis patients as well as in nonhemodialysis patients. A dramatically lower risk for sudden death in the initial AVR group would have been one of the major contributors for the lower long‐term mortality in hemodialysis patients with severe AS. Furthermore, markedly lower risk for HF hospitalization in the initial AVR strategy might also have contributed to the lower long‐term mortality in hemodialysis patients with severe AS. On the other hand, it should be noted that the long‐term mortality rate of hemodialysis patients with severe AS is very high even after AVR as compared with that in nonhemodialysis patients. Thourani et al reported the 5‐year mortality rate of 71.5% after AVR in 114 hemodialysis patients, which was comparable to 63.2% in 131 hemodialysis patients in the present study.[8](#jah32311-bib-0008){ref-type="ref"} The effect size of the initial AVR strategy relative to the conservative strategy for all‐cause death was smaller in hemodialysis patients than in nonhemodialysis patients, which could be explained by the extremely high rate of aortic valve procedure--related death in hemodialysis patients, predominantly occurring within 6 months of the AVR procedure. The major causes of aortic valve procedure--related death were infection and hemorrhage. When undergoing surgical AVR, hemodialysis patients are more likely to have an increased risk of perioperative infection and hemorrhage because of having higher preoperative morbidity, more concomitant diseases, and more severe atherosclerosis than nonhemodialysis patients, which may have increased postoperative mortality rates in hemodialysis patients. Therefore, reduction in the procedural mortality of AVR is essential to improve the overall mortality outcome of hemodialysis patients with severe AS. In this context, less invasive TAVI might be an attractive alternative to surgical AVR in hemodialysis patients with severe AS. Currently, there are only a few small studies reporting outcomes of TAVI in hemodialysis patients; reported 30‐day mortality rates included 14.0% (6/43) (transfemoral: 6.5%, and nontransfemoral: 33.3%) by Szerlip et al, 15.2% (5/33) by Dumonteil et al, and 0% (0/17) by Maeda et al.[16](#jah32311-bib-0016){ref-type="ref"}, [17](#jah32311-bib-0017){ref-type="ref"}, [18](#jah32311-bib-0018){ref-type="ref"} Further investigation on the role of TAVI in hemodialysis patients with severe AS is urgently needed.

Study Limitations {#jah32311-sec-0019}
-----------------

The present study has several limitations. First, its observational study design was prone to inherent bias. Particularly, the comparison between the initial AVR and conservative strategies would have been influenced by selection bias toward choosing less morbid patients in the initial AVR strategy. Also, the conservative group is a heterogeneous population and includes those with indications for surgery who were thought to be too risky and those not meeting indications for AVR because they were without symptoms. This could be noted as the Society of Thoracic Surgeons predicted risk of mortality is higher in the conservative group, yet the mean aortic pressure gradient is lower in this group. Despite an extensive multivariable adjustment, we could not deny the possibility of unmeasured confounders and selection bias. Also, we did not take the competing risk of death into account for the nonfatal outcomes and also the competing risks of various causes of death. Secondly, we did not evaluate the influence of the duration after introduction of hemodialysis on long‐term outcomes. Thirdly, the threshold to choose the AVR strategy and procedural outcomes of AVR might be different across the participating centers in this multicenter registry. Finally, the number of patients undergoing TAVI in our study was too small to clarify prognosis of hemodialysis patients undergoing TAVI.

Conclusions {#jah32311-sec-0020}
===========

Among hemodialysis patients with severe AS, the initial AVR strategy as compared with the conservative strategy was associated with significantly lower long‐term mortality risk, particularly the risk for sudden death, although the effect size for the survival benefit of the initial AVR strategy was smaller than that in the nonhemodialysis patients.
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**Appendix S1.** CURRENT AS Registry Investigators.

**Data S1.**

**Table S1.** Baseline Characteristics of Dialysis and Nondialysis Patients: Initial AVR Versus Conservative Groups

**Table S2.** Baseline Characteristics of Patients in the Initial AVR Group: Dialysis Versus Nondialysis Patients

**Table S3.** Baseline Characteristics in the Entire Cohort and in the Propensity‐Score Matched Cohort in Dialysis Patients: Initial AVR Versus Conservative Groups

**Table S4.** Baseline Characteristics in the Entire Cohort and in the Propensity‐Score Matched Cohort in Nondialysis Patients: Initial AVR Versus Conservative Groups

**Table S5.** Clinical Outcomes in the Propensity‐Score Matched Cohort in Dialysis Patients: Initial AVR Versus Conservative Groups

**Table S6.** Clinical Outcomes in the Propensity‐Score Matched Cohort in Nondialysis Patients: Initial AVR Versus Conservative Groups

**Table S7.** Procedural Characteristics of AVR in the Initial AVR Group: Dialysis Versus Nondialysis Patients

**Figure S1.** Cumulative incidence of surgical AVR or TAVI in the conservative group: dialysis vs nondialysis patients. AVR indicates aortic valve replacement; TAVI, transcatheter aortic valve replacement.

**Figure S2.** Propensity‐score matched cohort in dialysis and nondialysis patients for the sensitivity analysis. We used logistic regression model to develop propensity score for the choice of initial AVR with 15 independent variables relevant to the choice of initial AVR listed in Table [S3](#jah32311-sup-0001){ref-type="supplementary-material"}. Patients in the conservative group were matched to those in the initial AVR group using a 1:1 greedy matching technique. AS indicates aortic stenosis; AVR, aortic valve replacement.

**Figure S3.** Cumulative incidence of all‐cause death and sudden death in the propensity‐score matched cohort in (A) dialysis patients and (B) nondialysis patients: initial AVR vs conservative strategies. AVR indicates aortic valve replacement.

**Figure S4.** Cumulative incidences of (A) all‐cause death and (B) hospitalization for heart failure after surgical AVR in the initial AVR group in dialysis patients: mechanical valve vs bioprosthetic valve. Follow‐up was commenced on the day of surgical AVR. AVR indicates aortic valve replacement.
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Click here for additional data file.

[^1]: The CURRENT AS Registry Investigators are listed in Appendix S1.
